XML 34 R21.htm IDEA: XBRL DOCUMENT v3.21.2

Significant Accounting Policies (Details) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended	12 Months Ended
	Jan. 31, 2021	Aug. 31, 2020	Sep. 30, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalties		5.00%	5.00%
Revenues				$ 200,000
Liquidity discount (as a percent)			20.00%
1st Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			$ 100
Liquidity discount (as a percent)			30.00%
2nd Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			$ 100
Liquidity discount (as a percent)			40.00%
1st Patient in Dose Confirmation Study
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			$ 100
NDA Submission
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			300
1st FDA Approval in US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			5,000
2nd FDA Approval in US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			3,000
1st Regulatory Approval Outside US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			2,000
2nd Regulatory Approval Outside US
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			$ 2,000
Restricted shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement			41,000
Restricted shares | 1st Patient in Dose Confirmation Study
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			$ 5
Restricted shares | NDA Submission
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment			$ 15
Processa Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum proceeds from public offering		$ 15,000
Shares to be issued under agreement		825,000
Processa Pharmaceuticals, Inc | Restricted shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment	$ 5
Processa Pharmaceuticals, Inc | License agreement | Restricted shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares to be issued under agreement	41
Adjusted liquidity discount (as a percent)			5.00%
Processa Pharmaceuticals, Inc | License agreement | Restricted shares | 1st Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Adjusted liquidity discount (as a percent)			20.00%
Processa Pharmaceuticals, Inc | License agreement | Restricted shares | 2nd Year Anniversary of Effective Date
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Adjusted liquidity discount (as a percent)			25.00%

X

- Definition

Represents the percentage of adjusted liquidity discount.

+ References

No definition available.

+ Details

Name:	fenc_CollaborativeArrangementAdjustedLiquidityDiscountPercentage
Namespace Prefix:	fenc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of liquidity discount.

+ References

No definition available.

+ Details

Name:	fenc_CollaborativeArrangementLiquidityDiscountPercentage
Namespace Prefix:	fenc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of milestone payment entitled to receive under license agreement.

+ References

No definition available.

+ Details

Name:	fenc_CollaborativeArrangementMilestonePayment
Namespace Prefix:	fenc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the minimum proceeds from public offering as a Condition Precedent for grant of license.

+ References

No definition available.

+ Details

Name:	fenc_CollaborativeArrangementMinimumProceedsFromPublicOffering
Namespace Prefix:	fenc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the number of shares entitled to receive under license agreement.

+ References

No definition available.

+ Details

Name:	fenc_CollaborativeArrangementSharesToBeIssued
Namespace Prefix:	fenc_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of upfront payment entitled to receive under license agreement.

+ References

No definition available.

+ Details

Name:	fenc_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	fenc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the percentage of royalties to be received as consideration.

+ References

No definition available.

+ Details

Name:	fenc_RoyaltiesPercentage
Namespace Prefix:	fenc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_FirstYearAnniversaryOfEffectiveDateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_SecondYearAnniversaryOfEffectiveDateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_FirstPatientInDoseConfirmationStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_NdaSubmissionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_FirstFdaApprovalInUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_SecondFdaApprovalInUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_FirstRegulatoryApprovalOutsideUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	fenc_MilestoneEventAxis=fenc_SecondRegulatoryApprovalOutsideUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=fenc_ProcessaPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fenc_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: